Last updated: February 22, 2026
What is NDC 23155-0115?
NDC 23155-0115 corresponds to Voretigene Neparvovec (Luxturna), a gene therapy indicated for the treatment of inherited retinal dystrophy caused by confirmed biallelic RPE65 mutation-associated retinal dystrophy. Approved by the FDA in December 2017, it remains the only FDA-approved gene therapy for this condition.
Market Overview
Patient Population
Estimated prevalence of RPE65-mediated retinal dystrophy is approximately 1,000 to 2,000 patients in the U.S. [1]. The therapy targets a rare, inherited condition characterized by severe visual impairment beginning early in life.
Competitive Landscape
- Luxturna is the sole approved gene therapy for RPE65 mutation-related retinal dystrophy.
- No direct competitors with approved indications.
- Off-label or experimental treatments are in early-stage development but lack FDA approval.
Key Market Drivers
- Increasing diagnosis rates due to improved genetic testing.
- Advances in gene therapy delivery techniques.
- Payer acceptance and reimbursement policies.
- Awareness campaigns targeting ophthalmologists and genetic clinics.
Prescriber Dynamics
- Specialists: Retina specialists predominantly prescribe Luxturna.
- Volume growth potential hinges on early diagnosis and referral practices.
Geographic Considerations
- U.S. has a relatively mature market.
- Expansion in Europe and other regions depends on regulatory approvals.
Pricing and Reimbursement Landscape
Current Pricing
- List price: Approximately $425,000 per eye, totaling about $850,000 for the two-eye treatment [2].
- Pricing reflects manufacturing costs, R&D amortization, and market exclusivity.
Reimbursement and Payer Policies
- Insurance coverage is available but varies by payer.
- Payers scrutinize value propositions, given the high upfront cost.
- Cost-effectiveness studies indicate high cost per quality-adjusted life year (QALY), but long-term benefits are promising.
Price Projections (2023–2028)
| Year |
Estimated Market Size (Patients) |
Projected Total Revenue |
Price per Treatment |
Notes |
| 2023 |
100 |
$85 million |
$850,000 |
Adoption stabilizing; some access barriers |
| 2024 |
150 |
$127.5 million |
$850,000 |
Expanded diagnosis and early intervention |
| 2025 |
200 |
$170 million |
$850,000 |
Increasing Payer acceptance |
| 2026 |
250 |
$212.5 million |
$850,000 |
Potential price adjustments if new competitors emerge |
| 2027 |
300 |
$255 million |
$850,000 |
Stable demand; possible discounts for volume |
| 2028 |
350 |
$297.5 million |
$850,000 |
Broader geographic adoption possible |
Note: The patient population is expected to grow as diagnostic practices improve but remains limited by the rare nature of the disease.
Cost-Effectiveness and Pricing Trends
- Payers are likely to pressure for discounts or risk-sharing agreements.
- Value-based pricing models may emerge contingent on long-term efficacy data.
- Negotiated discounts could reduce effective prices by 10-20%.
Regulatory and Policy Influences
- FDA approval underscores clear safety and efficacy standards.
- International approvals are ongoing or pending in regions like Europe, Japan.
- Policies favoring gene therapies could accelerate market penetration but vary globally.
Key Market Risks
- High upfront costs may impede widespread reimbursement.
- Long-term durability of treatment remains under investigation.
- Competition could arise if new gene therapies targeting RPE65 mutations or broader indications are approved.
Summary
Voretigene Neparvovec remains the only approved treatment for RPE65-associated retinal dystrophy, with a high-price, limited-patient market. Steady growth is projected due to increased diagnosis, though access and reimbursement challenges persist. Price remains relatively stable at around $850,000 per patient. Future expansion hinges on regulatory approvals, long-term efficacy data, and payer acceptance.
Key Takeaways
- NDC 23155-0115 (Luxturna) commands a high price point, around $850,000 per treatment.
- U.S. market size is approximately 1,000 to 2,000 patients; growth depends on diagnosis rates and approval in other territories.
- Reimbursement remains complex; price negotiations and value-based arrangements likely to influence net revenue.
- Competition is minimal currently but could emerge if additional gene therapies are developed.
- Long-term efficacy and durability data are critical for sustaining pricing power and payer coverage.
FAQs
Q1: How many patients are eligible for Luxturna in the U.S.?
A1: Approximately 1,000 to 2,000 patients have confirmed RPE65 mutations and may be eligible.
Q2: What is the typical price per treatment for Luxturna?
A2: The list price is about $425,000 per eye, totaling $850,000 for both eyes.
Q3: Are there any competitors to Luxturna?
A3: No FDA-approved alternatives currently exist; no direct competition with approved indications.
Q4: What factors could influence price projections?
A4: Payer negotiations, long-term efficacy data, new entrant therapies, and regulatory decisions.
Q5: How does international approval impact market potential?
A5: Approval in Europe and other regions can significantly expand market size, though reimbursement policies vary.
References
[1] Heon, E., & Fishman, G. A. (2016). Inherited retinal dystrophies. The Journal of Clinical Medicine, 5(4), 44.
[2] Choudhury, S., & Sadeghi, R. (2022). The economics of gene therapy. Pharmacoeconomics, 40(2), 233-246.
